NASHUA, N.H. - iCAD, Inc. (NASDAQ: NASDAQ:ICAD), a provider of AI-powered solutions for early cancer detection, announced the appointment of Dr. Hedvig Hricak to its Board of Directors.
Dr. Hricak, a prominent figure in the field of radiology, brings over four decades of experience to the role, having recently stepped down as Chair of the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK) in January 2023.
Dr. Hricak's appointment is effective immediately. She continues her work at MSK as a faculty member, holds the Carroll and Milton Petrie Chair of Radiology, and is involved in various academic and advisory roles across prestigious institutions. Her career accomplishments include over 380 peer-reviewed research articles and numerous awards, such as the David Rall Medal from the National Academy of Medicine.
"We are thrilled to welcome Dr. Hricak to the iCAD Board of Directors," said Dana Brown, President, CEO, and Chairman of iCAD. Brown highlighted Dr. Hricak's vast experience and clinical expertise as invaluable assets for the company's mission to improve cancer detection and patient outcomes with AI technology.
Dr. Hricak expressed her honor in joining the board, emphasizing the opportunity to advance cancer care and support more efficient and accurate detection methods. Her global health initiatives have focused on promoting international education and collaboration to enhance access to oncologic imaging and cancer care.
iCAD's flagship product, the ProFound Breast Health Suite, is an AI-powered mammography analysis tool used in over 50 countries. The company estimates that it has analyzed more than 40 million mammograms in the past five years, nearly 30% of which were tomosynthesis.
This announcement is based on a press release statement from iCAD, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.